A UNITED HEALTH ECOSYSTEM

Be it controlling NCDs, precision medicine for cancer or eliminating Neglected Tropical Diseases (NTDs), health progress has been made possible by researchers in academia and in industry understanding diseases and developing vaccines and medicines, regulators incentivizing bringing of drugs to market, NGOs and foundations developing programs to deliver medicines, financial institutions defining innovative funding mechanisms, and healthcare providers training health workers. All are connected by the drive to understand and respond to the needs of the patient.

The cycle of care, from prevention to treatment to quality of life and cure, is both complex and highly personal. Health is impacted by a range of factors: from security to sanitation, and from geography to genetics. The research-based biopharmaceutical industry has played its part by bringing life-saving and life-prolonging medicines and vaccines to individuals, improving both personal and public health outcomes. Together, industry and others have reimagined how medicines make the journey from lab to patient.

The industry’s contribution to global health challenges has evolved over 50 years – enabled by a strong ethical code of practice. The way companies innovate and partner with others has delivered numerous health benefits to individuals and societies.

Global health progress relies on all actors sitting around the table: activists, governments, technical groups and industry.  

David Heymann,  
Professor, Infectious Disease Epidemiology, London School of Hygiene & Tropical Medicine

INTERNATIONAL MULTILATERAL INSTITUTIONS

RESEARCH-BASED BIOPHARMACEUTICAL MANUFACTURERS

INSURERS

REGULATORS

DEVELOPMENT BANKS

PUBLIC HEALTH DEPARTMENTS

HEALTH TECHNOLOGY PROVIDERS

HEALTH WORKER ORGANIZATIONS

HEALTHCARE PROVIDERS

INVESTORS

PATIENTS

NATIONAL HEALTHCARE SYSTEM

NGOs

HOSPITALS

FOUNDATIONS

ACADEMIA AND UNIVERSITIES